SNMMI Abstract of the Year: [177Lu]Lu-PSMA-617 extends progression-free survival with manageable safety profile in taxane-naïve advanced prostate cancer patients
Toronto, Ontario (Embargoed until 9:30 a.m. EDT, Sunday, June 9, 2024)—New data on prolonged prostate-specific antigen (PSA) progression and adverse...
![SNMMI Abstract of the Year: [177Lu]Lu-PSMA-617 extends progression-free survival with](https://scienmag.com/wp-content/plugins/wp-fastest-cache-premium/pro/images/blank.gif)